NicOx, Merck expand NO donation joint research program
NicOx and Merck said that the approach may be used to develop new classes of NO-donating new molecular entities (NMEs), designed to offer a different mechanism for controlling
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.